Cardlytics (CDLX) Fundamental Analysis: Revenue, Earnings & Valuation

9.13 / 10

Outperform

Fundamental analysis rates Cardlytics Outperform with a 9.13 score. EPS and diluted EPS YoY growth are strong, net profit growth is solid, and Asset‑MV is favorable. However, ROE is weak, cash‑flow ratios lag, and equity ratio shows modest leverage.

Analysis Checks(5/10)

Shareholders’ equity attributable to parent company / Total liabilities (%)

Value-0.02

Score1/3

Weight-4.15%

1M Return-0.73%

ROE (diluted) (YoY growth rate %)

Value1627.09

Score0/3

Weight-11.92%

1M Return-2.74%

Equity ratio (Total liabilities / Shareholders’ equity attributable to parent company) (%)

Value4.04

Score1/3

Weight-3.61%

1M Return-0.63%

Net cash flow from operating activities / Operating revenue (%)

Value3.98

Score0/3

Weight-13.38%

1M Return-2.73%

Net income-Revenue

Value-0.04

Score2/3

Weight5.06%

1M Return0.98%

Basic earnings per share (YoY growth rate %)

Value50.13

Score3/3

Weight15.57%

1M Return2.69%

Net cash flow from operating activities (YoY growth rate %)

Value205.28

Score1/3

Weight-0.24%

1M Return-0.04%

Diluted earnings per share (YoY growth rate %)

Value50.13

Score3/3

Weight12.95%

1M Return2.21%

Net profit attributable to parent company shareholders (YoY growth rate %)

Value45.33

Score3/3

Weight14.61%

1M Return2.50%

Asset-MV

Value-0.55

Score3/3

Weight85.11%

1M Return12.37%

Is CDLX undervalued or overvalued?

CDLX scores 9.13/10 on fundamentals and holds a Discounted valuation at present. Backed by its -326.02% ROE, -44.36% net margin, -0.56 P/E ratio, -8.97 P/B ratio, and 50.13% earnings growth, these metrics solidify its Outperform investment rating.